BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 37140883)

  • 1. Genome-wide profiling of patient-derived glioblastoma stem-like cells reveals recurrent genetic and transcriptomic signatures associated with brain tumors.
    Lazzarini E; Silvestris DA; Benvenuto G; Osti D; Fattore L; Paterra R; Finocchiaro G; Malatesta P; Daga A; Gallotti AL; Galli R; Pelicci G; Tesei A; Bedeschi M; Pallini R; Pasqualini L; Romualdi C; Gallo A; Ricci-Vitiani L; Indraccolo S
    J Neurooncol; 2023 May; 163(1):47-59. PubMed ID: 37140883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genome-wide methylomic and transcriptomic analyses identify subtype-specific epigenetic signatures commonly dysregulated in glioma stem cells and glioblastoma.
    Pangeni RP; Zhang Z; Alvarez AA; Wan X; Sastry N; Lu S; Shi T; Huang T; Lei CX; James CD; Kessler JA; Brennan CW; Nakano I; Lu X; Hu B; Zhang W; Cheng SY
    Epigenetics; 2018; 13(4):432-448. PubMed ID: 29927689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular heterogeneity in a patient-derived glioblastoma xenoline is regulated by different cancer stem cell populations.
    Garner JM; Ellison DW; Finkelstein D; Ganguly D; Du Z; Sims M; Yang CH; Interiano RB; Davidoff AM; Pfeffer LM
    PLoS One; 2015; 10(5):e0125838. PubMed ID: 25955030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maintenance of primary tumor phenotype and genotype in glioblastoma stem cells.
    Wakimoto H; Mohapatra G; Kanai R; Curry WT; Yip S; Nitta M; Patel AP; Barnard ZR; Stemmer-Rachamimov AO; Louis DN; Martuza RL; Rabkin SD
    Neuro Oncol; 2012 Feb; 14(2):132-44. PubMed ID: 22067563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stem cell signature in glioblastoma: therapeutic development for a moving target.
    Nakano I
    J Neurosurg; 2015 Feb; 122(2):324-30. PubMed ID: 25397368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. REST-DRD2 mechanism impacts glioblastoma stem cell-mediated tumorigenesis.
    Marisetty AL; Lu L; Veo BL; Liu B; Coarfa C; Kamal MM; Kassem DH; Irshad K; Lu Y; Gumin J; Henry V; Paulucci-Holthauzen A; Rao G; Baladandayuthapani V; Lang FF; Fuller GN; Majumder S
    Neuro Oncol; 2019 Jun; 21(6):775-785. PubMed ID: 30953587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dexamethasone-mediated oncogenicity in vitro and in an animal model of glioblastoma.
    Luedi MM; Singh SK; Mosley JC; Hassan ISA; Hatami M; Gumin J; Andereggen L; Sulman EP; Lang FF; Stueber F; Fuller GN; Colen RR; Zinn PO
    J Neurosurg; 2018 Dec; 129(6):1446-1455. PubMed ID: 29328002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Core pathway mutations induce de-differentiation of murine astrocytes into glioblastoma stem cells that are sensitive to radiation but resistant to temozolomide.
    Schmid RS; Simon JM; Vitucci M; McNeill RS; Bash RE; Werneke AM; Huey L; White KK; Ewend MG; Wu J; Miller CR
    Neuro Oncol; 2016 Jul; 18(7):962-73. PubMed ID: 26826202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined PDK1 and CHK1 inhibition is required to kill glioblastoma stem-like cells in vitro and in vivo.
    Signore M; Pelacchi F; di Martino S; Runci D; Biffoni M; Giannetti S; Morgante L; De Majo M; Petricoin EF; Stancato L; Larocca LM; De Maria R; Pallini R; Ricci-Vitiani L
    Cell Death Dis; 2014 May; 5(5):e1223. PubMed ID: 24810059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. pRB immunostaining in the differential diagnosis between pleomorphic xanthoastrocytoma and glioblastoma with giant cells.
    Barresi V; Simbolo M; Ciaparrone C; Pedron S; Mafficini A; Scarpa A
    Histopathology; 2022 Nov; 81(5):661-669. PubMed ID: 35945679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markers.
    Korshunov A; Ryzhova M; Hovestadt V; Bender S; Sturm D; Capper D; Meyer J; Schrimpf D; Kool M; Northcott PA; Zheludkova O; Milde T; Witt O; Kulozik AE; Reifenberger G; Jabado N; Perry A; Lichter P; von Deimling A; Pfister SM; Jones DT
    Acta Neuropathol; 2015 May; 129(5):669-78. PubMed ID: 25752754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cells isolated from residual intracranial tumors after treatment express iPSC genes and possess neural lineage differentiation plasticity.
    Palanichamy K; Jacob JR; Litzenberg KT; Ray-Chaudhury A; Chakravarti A
    EBioMedicine; 2018 Oct; 36():281-292. PubMed ID: 30269995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Wnt/β-catenin signaling is a key downstream mediator of MET signaling in glioblastoma stem cells.
    Kim KH; Seol HJ; Kim EH; Rheey J; Jin HJ; Lee Y; Joo KM; Lee J; Nam DH
    Neuro Oncol; 2013 Feb; 15(2):161-71. PubMed ID: 23258844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrative Exome and Transcriptome Analysis of Conjunctival Melanoma and Its Potential Application for Personalized Therapy.
    Demirci H; Demirci FY; Ciftci S; Elner VM; Wu YM; Ning Y; Chinnaiyan A; Robinson DR
    JAMA Ophthalmol; 2019 Dec; 137(12):1444-1448. PubMed ID: 31647501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic Evolution of Glioblastoma Stem-Like Cells From Primary to Recurrent Tumor.
    Orzan F; De Bacco F; Crisafulli G; Pellegatta S; Mussolin B; Siravegna G; D'Ambrosio A; Comoglio PM; Finocchiaro G; Boccaccio C
    Stem Cells; 2017 Nov; 35(11):2218-2228. PubMed ID: 28895245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New insights for precision treatment of glioblastoma from analysis of single-cell lncRNA expression.
    Meng Q; Zhang Y; Li G; Li Y; Xie H; Chen X
    J Cancer Res Clin Oncol; 2021 Jul; 147(7):1881-1895. PubMed ID: 33693962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRAF V600E, TERT promoter mutations and CDKN2A/B homozygous deletions are frequent in epithelioid glioblastomas: a histological and molecular analysis focusing on intratumoral heterogeneity.
    Nakajima N; Nobusawa S; Nakata S; Nakada M; Yamazaki T; Matsumura N; Harada K; Matsuda H; Funata N; Nagai S; Nakamura H; Sasaki A; Akimoto J; Hirato J; Yokoo H
    Brain Pathol; 2018 Sep; 28(5):663-673. PubMed ID: 29105198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular landscape of IDH-wild-type, H3-wild-type glioblastomas of adolescents and young adults.
    Shi ZF; Li KK; Huang QJ; Wang WW; Kwan JS; Chen H; Liu XZ; Li WC; Chan DT; Zhang ZY; Mao Y; Ng HK
    Neuropathol Appl Neurobiol; 2022 Jun; 48(4):e12802. PubMed ID: 35191072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cerebellar glioblastoma: a clinical series with contemporary molecular analysis.
    Hong B; Banan R; Christians A; Nakamura M; Lalk M; Lehmann U; Hartmann C; Krauss JK
    Acta Neurochir (Wien); 2018 Nov; 160(11):2237-2248. PubMed ID: 30203362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. On-target JAK2/STAT3 inhibition slows disease progression in orthotopic xenografts of human glioblastoma brain tumor stem cells.
    Stechishin OD; Luchman HA; Ruan Y; Blough MD; Nguyen SA; Kelly JJ; Cairncross JG; Weiss S
    Neuro Oncol; 2013 Feb; 15(2):198-207. PubMed ID: 23262510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.